Banu K Arun1, Susan K Peterson2, Lilian E Sweeney3, Rachel D Bluebond4, Rebecca S S Tidwell5, Sukh Makhnoon2, Anne C Kushwaha3. 1. Department of Breast Medical Oncology and Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Houston Breast Screening Network, Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: Genetic evaluation and testing for hereditary breast and ovarian cancer (HBOC) remain suboptimal. The authors evaluated the feasibility of using a screening tool at a breast imaging center to increase HBOC assessment referrals. METHODS: A brief questionnaire based on the National Comprehensive Cancer Network HBOC genetic counseling referral guidelines was developed and added to the standard intake forms of patients undergoing mammography at a community breast imaging center from 2012 through 2015. Patients who met the criteria in the guidelines were referred for genetic counseling. RESULTS: A total of 34,851 patients were screened during the study period, and 1246 (4%) patients were found to be eligible for referral; 245 of these patients made a genetic counseling appointment, and 142 patients received genetic counseling. Forty patients (28%) had a personal history of breast cancer but were not previously tested. Following counseling, 105 patients were tested for BRCA1/2. Eight patients (8%) tested positive for a pathogenic mutation and nine (9%) had a variant of unknown significance. Although they tested negative, many patients met the criteria to add breast magnetic resonance imaging to their screening due to greater than 20% lifetime breast cancer risk based on their family cancer history. This study led to improved clinical risk management in 67% of the patients who underwent genetic counseling. CONCLUSIONS: This study shows that large-scale screening of patients for HBOC syndromes at time of breast imaging is practical and highly feasible. The screening tool identified women with actionable BRCA1/2 mutations and mutation-negative but high-risk women, leading to significant changes in their risk management; these women would otherwise have been missed. LAY SUMMARY: Hereditary breast and ovarian cancer (HBOC) caused by pathogenic mutations in breast cancer genes (BRCA1/BRCA2) increase an individual's lifetime risk of getting HBOC. Identifying these high-risk individuals and using proven preventive clinical risk management strategies can significantly reduce their lifetime risk of HBOC. Using an innovative family cancer history questionnaire, 34,000 women were screened at a community breast imaging center, and genetic counseling and testing were provided to eligible women from the screening. Several women at high risk for HBOC were identified and this led to positive clinical risk management changes. These women would have been missed if not for intervention.
BACKGROUND: Genetic evaluation and testing for hereditary breast and ovarian cancer (HBOC) remain suboptimal. The authors evaluated the feasibility of using a screening tool at a breast imaging center to increase HBOC assessment referrals. METHODS: A brief questionnaire based on the National Comprehensive Cancer Network HBOC genetic counseling referral guidelines was developed and added to the standard intake forms of patients undergoing mammography at a community breast imaging center from 2012 through 2015. Patients who met the criteria in the guidelines were referred for genetic counseling. RESULTS: A total of 34,851 patients were screened during the study period, and 1246 (4%) patients were found to be eligible for referral; 245 of these patients made a genetic counseling appointment, and 142 patients received genetic counseling. Forty patients (28%) had a personal history of breast cancer but were not previously tested. Following counseling, 105 patients were tested for BRCA1/2. Eight patients (8%) tested positive for a pathogenic mutation and nine (9%) had a variant of unknown significance. Although they tested negative, many patients met the criteria to add breast magnetic resonance imaging to their screening due to greater than 20% lifetime breast cancer risk based on their family cancer history. This study led to improved clinical risk management in 67% of the patients who underwent genetic counseling. CONCLUSIONS: This study shows that large-scale screening of patients for HBOC syndromes at time of breast imaging is practical and highly feasible. The screening tool identified women with actionable BRCA1/2 mutations and mutation-negative but high-risk women, leading to significant changes in their risk management; these women would otherwise have been missed. LAY SUMMARY: Hereditary breast and ovarian cancer (HBOC) caused by pathogenic mutations in breast cancer genes (BRCA1/BRCA2) increase an individual's lifetime risk of getting HBOC. Identifying these high-risk individuals and using proven preventive clinical risk management strategies can significantly reduce their lifetime risk of HBOC. Using an innovative family cancer history questionnaire, 34,000 women were screened at a community breast imaging center, and genetic counseling and testing were provided to eligible women from the screening. Several women at high risk for HBOC were identified and this led to positive clinical risk management changes. These women would have been missed if not for intervention.
Authors: Douglas K Owens; Karina W Davidson; Alex H Krist; Michael J Barry; Michael Cabana; Aaron B Caughey; Chyke A Doubeni; John W Epling; Martha Kubik; C Seth Landefeld; Carol M Mangione; Lori Pbert; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng; John B Wong Journal: JAMA Date: 2019-08-20 Impact factor: 56.272
Authors: Anand Narayan; Alexander Fischer; Zihe Zhang; Ryan Woods; Elizabeth Morris; Susan Harvey Journal: Breast Cancer Res Treat Date: 2017-05-15 Impact factor: 4.872
Authors: Janice S Kwon; Angelica M Gutierrez-Barrera; Diana Young; Charlotte C Sun; Molly S Daniels; Karen H Lu; Banu Arun Journal: J Clin Oncol Date: 2010-08-23 Impact factor: 44.544
Authors: Julie L Jones; Kevin S Hughes; Daniel B Kopans; Richard H Moore; Marissa Howard-McNatt; Sherwood S Hughes; Nancy Y Lee; Constance A Roche; Nancy Siegel; Michele A Gadd; Barbara L Smith; James S Michaelson Journal: Clin Breast Cancer Date: 2005-04 Impact factor: 3.225
Authors: M H Gail; L A Brinton; D P Byar; D K Corle; S B Green; C Schairer; J J Mulvihill Journal: J Natl Cancer Inst Date: 1989-12-20 Impact factor: 13.506
Authors: Elissa M Ozanne; Andrea Loberg; Sherwood Hughes; Christine Lawrence; Brian Drohan; Alan Semine; Michael Jellinek; Claire Cronin; Frederick Milham; Dana Dowd; Caroline Block; Deborah Lockhart; John Sharko; Georges Grinstein; Kevin S Hughes Journal: Breast J Date: 2009 Mar-Apr Impact factor: 2.431
Authors: Rita Kukafka; Samuel Pan; Thomas Silverman; Tianmai Zhang; Wendy K Chung; Mary Beth Terry; Elaine Fleck; Richard G Younge; Meghna S Trivedi; Julia E McGuinness; Ting He; Jill Dimond; Katherine D Crew Journal: JAMA Netw Open Date: 2022-07-01